Comment from BPI Labs, LLC
AnonymousSupportBusiness
Summary: BPI Labs, a laboratory entity, is requesting that the FDA add Semaglutide and Tirzepatide to the 503B Bulk Drug Substances List. They argue that including these substances will improve patient access to high-quality, quality-controlled compounded medications for metabolic disorders like Type 2 Diabetes and obesity.
BPI Labs submits this comment in support of adding Semaglutide (UNII: 53AXN4NNHX) and Tirzepatide (UNII: OYN3CCI6QE) to the 503B Bulk Drug Substances List under Docket No. FDA-2015-N-3469.
Both Semaglutide and Tirzepatide are well-established peptide-based therapeutic agents with significant clinical utility, particularly in the management of metabolic disorders, including Type 2 Diabetes and obesity. Given the increasing demand for these agents in patient care, particularly in specialized and compounded formulations, their availability under 503B outsourcing facilities would enhance patient access and ensure quality-controlled production standards.
We believe that including these substances on the 503B bulk drug substances list aligns with the FDA's mission to promote patient safety while maintaining regulatory oversight of high-quality compounded medications. BPI Labs strongly urges the FDA to approve these nominations to expand patient treatment options and support healthcare providers in addressing unmet medical needs.
We appreciate the FDA’s consideration of this recommendation and look forward to continued engagement on this matter.